Ionis Pharmaceuticals Q2 EPS $(0.41) Beats $(0.90) Estimate, Sales $188.00M Beat $138.83M Estimate
Portfolio Pulse from Benzinga Newsdesk
Ionis Pharmaceuticals reported Q2 earnings per share of $(0.41), beating the analyst consensus estimate of $(0.90) by 54.44%. The company also reported quarterly sales of $188.00 million, surpassing the analyst consensus estimate of $138.83 million by 35.42%. This represents a 26.79% increase in earnings and a 40.30% increase in sales compared to the same period last year.
August 09, 2023 | 11:23 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ionis Pharmaceuticals reported better than expected Q2 earnings and sales, which could positively impact the stock in the short term.
Ionis Pharmaceuticals reported Q2 earnings and sales that beat analyst estimates. This positive financial performance could lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100